Source: Global Tuberculosis Report 2015
http://www.who.int/tb/publications/global_report/en/
Accessed: 05.10.2019
Guidelines on obstructive sleep apnea in India.
F.No. INDO/FRC/442/2008-IHD | INDIAN COUNCIL OF MEDICAL RESEARCH
| New Delhi, the 1st July, 2014 | OFFICE MEMORANDUM
A summary of the national drug situation
In 2014 UNICEF, WHO and the World Bank report new joint estimates of child malnutrition using available data up to 2013 The Interactive dashboard allows users to generate a variety of graphs and charts, using the newest joint estimates of prevalence and numbers for child stunting, underweight, overw...eight, wasting and severe wasting. Users can select the different regional country groupings of the UN, MDG, UNICEF, WHO regions as well as World Bank income groups and geographic regions to present the data.
A summary of 4 pages presents the key findings for each indicator, an introduction to the dashboard and updates on methods
more
10th edition
The IDF Diabetes Atlas 10th edition provides detailed information on the estimated and projected prevalence of diabetes, globally, by region, country and territory, for 2021, 2030 and 2045. It draws attention to the growing impact of diabetes across the world and highlights proven and ...effective actions that governments and policy-makers must urgently take to tackle it.
more
PLoS ONE 12(7): e0180996. https://doi.org/10.1371/journal.pone.0180996
Volume 2019, Article ID 4157574, 7 pages
https://doi.org/10.1155/2019/4157574
Version 3 Dec. 2020
The COVID-19 Vaccine Introduction Readiness Assessment Tool (VIRAT)2, developed by WHO in collaboration with PAHO is a tool for the national authorities, that allows for the establishment of a roadmap and to monitor progress in the preparation of the activities related to the in...troduction of the COVID-19 vaccines.
more
updated version: 04/10/2021
Information about vaccine administration
COVID-19, General Epidemiological Surveillance Guidelines (Version 6)
The UNHCR WASH Monitoring System includes monitoring of refugee health facilities following the Joint Monitoring Program (JMP) guidelines, model questions and standard indicators. All refugee health facilities should be surveyed at least once a year. Indicators are tracked on the Refugee WASH in Hea...lth Facilities Dashboard.
more
The World Health Organization Global TB Report provides a comprehensive and up-to-date assessment of the TB epidemic, and progress in the response, at global, regional and country levels.
The 2022 edition features data on disease trends and the response to the epidemic from 215 countries and area...s, including all 194 World Health Organization (WHO) Member States. It provides a comprehensive and up-to-date assessment of the TB epidemic, progress in the response at global, regional and country levels, as well as on the impact of the COVID-19 pandemic on TB services.
TB remains one of the top infectious killers in the world. This year’s report presents data on an increase in the number of people falling ill with TB and drug resistant TB for the first time in many years. Increases were also reported on the number of TB deaths, highlighting the severe impact of the COVID-19 pandemic and other crises on the TB response that has reversed years of progress. It also presents the status of progress towards targets set at the first-ever United Nations General Assembly high-level meeting on TB in 2018 as well as the targets of the WHO End TB Strategy and the Sustainable Development Goals.
more
The cardiovascular disease continuum begins with risk factors such as diabetes mellitus (DM), progresses to vasculopathy and myocardial dysfunction, and finally ends with cardiovascular death. Diabetes is associated with a 2- to 4-fold increased risk for heart failure (HF). Moreover, HF patients wit...h DM have a worse prognosis than those without DM. Diabetes can cause myocardial ischemia via micro- and macrovasculopathy and can directly exert deleterious effects on the myocardium. Hyperglycemia, hyperinsulinemia, and insulin resistance can cause alterations in vascular homeostasis. Then, reduced nitric oxide and increased reactive oxygen species levels favor inflammation leading to atherothrombotic progression and myocardial dysfunction. The classification, diagnosis, and treatment of HF for a patient with and without DM remain the same. Until now, drugs targeting neurohumoral and metabolic pathways improved mortality and morbidity in HF with reduced ejection fraction (HFrEF). Therefore, all HFrEF patients should receive guideline-directed medical therapy. By contrast, drugs modulating neurohumoral activity did not improve survival in HF with preserved ejection fraction (HFpEF) patients. Trials investigating whether sodium-glucose cotransporter-2 inhibitors are effective in HFpEF are on-going. This review will summarize the epidemiology, pathophysiology, and treatment of HF in diabetes.
more